Table 1 Summary of the expression, regulation, and functions of miR-205 in different cancers.

Prostate cancer

Downregulated

TFs (p63/ΔNp63α, HIF-1α), hypermetilation, deacetylation

Tumor-suppressor

N-chimerin, E2F1, E2F5, ZEB2, protein kinase Cε, MED1, MAPK, AR

^{13,20,21,37,39,40,45,48}

Breast cancer

Downregulated (TNBC)

TF (p53), hypermetilation, deacetylation, lncRNA (linc-ROR)

Tumor-suppressor, oncogene

ZEB1, ZEB2, PTEN, HER3, VEGFA, FGF2

^{8,11,22,23,38,65}

Lung cancer

Downregulated (adenocarcinoma) or upregulated (squamous cell carcinoma)

Hypermethylation, deacetylation

Tumor-suppressor or oncogene; biomarker

PTEN, PHLPP2, RUNX1

^35,41,51

Renal cancer

Downregulated

lncRNA (LINC00152)

Tumor-suppressor

Src-family members, Ras/Raf/ERK1/2

^25,66

Head and neck cancer

Upregulated

TF (p53)

Oncogene, prognostic marker

PTEN

³⁰

Melanoma

Downregulated

TFs (p73/ΔNp73)

Tumor-suppressor

E2F1, BCL2, VEGF

²⁴

Bladder cancer

Downregulated invasive bladder cancer) or upregulated (non-invasive bladder cancer)

TF (ΔNp63α, Twist1), hypermetilation, lncRNA (HOTAIR)

Tumor-suppressor or oncogene

ZEB1, ZEB2

^36,47,67

Endometrial cancer

Upregulated

lncRNAs (RP11–395G23.3 and LA16c-313D11.11)

Oncogene, prognostic marker

PTEN, ESRRG

^26,27